NP2 Enkephalin Phase I trial shows pain reduction: Diamyd Medical
Diamyd claims that NP2 Enkephalin is the first drug candidate from its proprietary NTDDS (Nerve Targeting Drug Delivery System)platform focally delivering therapeutic compounds directly to the nervous system.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.